Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mds.27574 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Parkinson's disease: symptoms and medications at the end of life.
BMJ Support Palliat Care
January 2024
Medicine for Older People, North Bristol NHS Trust, Bristol, UK.
Objectives: People with Parkinson's disease (PwP) have a high palliative symptom burden throughout their disease course, equivalent to advanced malignancy. We aim to establish trends in symptom frequency and prescribing in the 72 hours prior to death for PwP.
Methods: Retrospective case note review of PwP who died between February 2019 and September 2020.
A note on rotigotine for restless legs syndrome after renal transplantation.
Mov Disord
January 2019
Neurogenetics, Instituto de Investigación Sanitaria de Santiago-SERGAS Santiago de Compostela, Spain.
Reply to: A note on rotigotine for restless legs syndrome after renal transplantation.
Mov Disord
January 2019
Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany.
Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy.
Neuropsychiatr Dis Treat
June 2014
IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Transdermal rotigotine (RTG) is a non-ergot dopamine agonist (D3>D2>D1), and is indicated for use in early and advanced Parkinson's disease (PD). RTG patch has many potential advantages due to the immediacy of onset of the therapeutic effect. Of note, intestinal absorption is not necessary and drug delivery is constant, thereby avoiding drug peaks and helping patient compliance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!